会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 63. 发明公开
    • 스컬캅플라본Ⅱ 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 천식의 예방 또는 치료용 약학적 조성물
    • 含有SKFLCAPFLAVONE II或其药学上可接受的盐的药物组合物用于预防或治疗ASTHMA
    • KR1020130120849A
    • 2013-11-05
    • KR1020120044045
    • 2012-04-26
    • 한국생명공학연구원
    • 안경섭오세량장하영권옥경김두영김정희박미정이형규진영원
    • A61K31/045A61K31/05A61K31/122A61P11/06
    • The present invention relates to a pharmaceutical composition containing skullcapflavone II or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating asthma. Specifically, skullcapflavone II compounds suppress body weight reduction caused by asthma, the generation of IgE, ovoalbumin-specific IgE, interleukin-4, 5, and 13, and MMP-9 in serum and a bronchoalveolar lavage fluid, alleviate airway hypersensitivity responses, and prevent collagen precipitation around bronchial tubes, inflammatory cell infiltration into bronchial tubes, and mucous secretion in bronchial tubes with low hepatotoxicity. In addition, the skullcapflavone II compounds reduce the concentration of TGF-beta 1, increase the expression of Smad7, and suppress the concentration of pSmad2/3, thereby being used as an active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma. [Reference numerals] (AA) Gold E3-PR-13 (skullcapflavone ii);(BB) Document: Chem. Pharm. Bull. (1980), 28(3), 708-716;(CC) C (document) (DMSO-d_s)
    • 本发明涉及含有骷髅头黄酮II或其药学上可接受的盐作为预防或治疗哮喘的有效成分的药物组合物。 具体来说,骷髅黄酮II化合物抑制哮喘引起的体重减轻,血清和支气管肺泡灌洗液中产生IgE,卵清蛋白特异性IgE,白细胞介素-4,5和13以及MMP-9,减轻气道超敏反应, 预防支气管周围的胶原沉淀,炎症细胞浸润到支气管,以及低肝毒性的支气管中的粘液分泌。 此外,骷髅黄素II化合物降低TGF-β1的浓度,增加Smad7的表达,抑制pSmad2 / 3的浓度,从而作为预防或治疗支气管哮喘的药物组合物的活性成分。 (AA)金E3-PR-13(骷髅黄酮ii);(BB)文献:Chem。 医药。 公牛。 (1980),28(3),708-716;(CC)C(文献)(DMSO-d_s)
    • 66. 发明公开
    • 로도덴드론 알붐 추출물 또는 이의 분획물을 함유하는 염증성 질환의 예방 및 치료를 위한 약학적 조성물
    • 包含用于预防和治疗炎症性疾病的罗丹明乳液的提取物或片段的药物组合物
    • KR1020130001140A
    • 2013-01-03
    • KR1020120066296
    • 2012-06-20
    • 한국생명공학연구원
    • 오세량안경섭권옥경박지원이중구이형규장하영백진협
    • A61K36/45A61P29/00A61P17/00
    • PURPOSE: A pharmaceutical composition containing Rhododendron album Blume extract or a fraction thereof for preventing and treating inflammatory diseases is provided to suppress IL-1 beta secretion and iNOS protein expression. CONSTITUTION: A pharmaceutical composition for preventing and treating inflammatory diseases contains Rhododendron album Blume extract or a fraction thereof as an active ingredient. The extract is prepared using water, low carbon number alcohol of C1-C2, or a mixture thereof. The fraction is prepared using n-hexane, chloroform, ethyl acetate, or butanol. An external use formulation for preventing and treating inflammatory diseases contains the extract or fraction as an active ingredient. A cosmetic composition or a health food for preventing and treating inflammatory diseases contains the extract or fraction as an active ingredient. [Reference numerals] (AA) Yield of nitric oxide; (BB) Rhododendron album(ug/ml)
    • 目的:提供含有杜鹃花专利Blume提取物或其部分用于预防和治疗炎性疾病的药物组合物以抑制IL-1β分泌和iNOS蛋白表达。 构成:用于预防和治疗炎性疾病的药物组合物含有杜鹃花专辑Blume提取物或其一部分作为活性成分。 提取物是使用C1-C2的低碳数醇或其混合物制备的。 使用正己烷,氯仿,乙酸乙酯或丁醇制备级分。 用于预防和治疗炎性疾病的外用制剂含有提取物或级分作为活性成分。 用于预防和治疗炎性疾病的化妆品组合物或保健食品含有提取物或级分作为活性成分。 (AA)一氧化氮的产率; (BB)杜鹃花专辑(ug / ml)
    • 68. 发明公开
    • Neuropilin 1 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법
    • 使用神经病毒的方法诊断和筛选哮喘1
    • KR1020120003187A
    • 2012-01-10
    • KR1020100063905
    • 2010-07-02
    • 한국생명공학연구원
    • 이형규안경섭윤유식최병휘권옥경김세미김희성오세량육지은장하영
    • C12Q1/68C12N15/12G01N33/53
    • A61K31/7088A61K39/3955C07K14/71C12Q1/6883C12Q2600/156G01N2800/122G01N2800/24C12Q1/6837C12Q2600/178G01N33/5302
    • PURPOSE: A method for screening an agent for asthma using a kit containing neuropilin(NRP) gene is provided to reduce asthma-related MMP9 mRNA, protein expression and enzyme and promote activity. CONSTITUTION: A DNA microarray for diagnosing asthma contains neurophilin 1 gene or complementary molecule thereof. A NRP1 gene has a base sequence of sequence number 1. A kit for diagnosing asthma contains the DNA microarray. The kit comprises a primer set of a forward primer of sequence number 2 and a reverse primer of sequence number 3. A method for detecting proteins for providing information for diagnosing asthma comprises: a step of measuring NRP1 expression level from a sample of an experimental group; a step of comparing expression level of NRP1 with the expression level of a control group; and a step of determining possibility of asthma attack. The sample is blood, serum, plasma, urine, tear, saliva, sputum, or lung secretion. A pharmaceutical composition for treating asthma contains an agent for inhibiting NRP1 gene expression or activity.
    • 目的:提供使用含有神经胶质蛋白(NRP)基因的试剂盒进行哮喘药物筛选的方法,以减少哮喘相关的MMP9mRNA,蛋白质表达和酶促进活性。 构成:用于诊断哮喘的DNA微阵列含有神经生长素1基因或其互补分子。 NRP1基因具有序列号1的碱基序列。用于诊断哮喘的试剂盒含有DNA微阵列。 该试剂盒包含序列号为2的正向引物的引物组和序列号3的反向引物。用于检测提供用于诊断哮喘的信息的蛋白质的方法包括:从实验组的样品测量NRP1表达水平的步骤 ; 将NRP1的表达水平与对照组的表达水平进行比较的步骤; 并确定哮喘发作的可能性。 样品为血液,血清,血浆,尿液,泪液,唾液,痰液或肺部分泌物。 用于治疗哮喘的药物组合物含有抑制NRP1基因表达或活性的药剂。
    • 70. 发明公开
    • 아크릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
    • 用于预防或治疗含有丙烯酰胺衍生物或药物可接受的作为活性成分的药物的炎症疾病的药物组合物
    • KR1020110055922A
    • 2011-05-26
    • KR1020090112547
    • 2009-11-20
    • 한국생명공학연구원
    • 이형규오세량안경섭진영원이상구김두영김수현권옥경육지은이일수
    • A61K31/165A61P29/00A61P11/06A61P37/08
    • PURPOSE: A pharmaceutical composition containing acrylamide derivatives is provided to suppress secretion or generation of leukotriene and to prevent and treat inflammatory diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains an acrylamide derivative of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, R is hydrogen or alkoxy of C1-C4. The acrylamide derivative of chemical formula 1 is (E)-4'-hydroxy-3'-methoxystyryl 3-(4-hydroxyphenyl)propanoate or (R,E)-4'-hydroxy-3'-methoxystyryl-3-(4-hydroxyphenyl)-7-methoxypropanoate. A method for preparing the acrylamide derivatives comprises: a step of extracting Solanum nigrum with water, alcohol of C1-C4, or mixture solvent; a step of suspending the extract in the water and adding same amount of ethyl acetate to obtain an ethyl acetate fraction(first fraction); a step of performing silicagel column chromatography of the ethyl acetate fraction to obtain a second fraction(1-6); a step of performing silicagel column chromatography of the 5th fraction of the second fraction to obtain a third fraction(5-1~5-7); and a step of performing reverse phase-18 column chromatography.
    • 目的:提供含有丙烯酰胺衍生物的药物组合物,以抑制白细胞三烯的分泌或产生并预防和治疗炎性疾病。 构成:用于预防或治疗炎性疾病的药物组合物含有化学式1的丙烯酰胺衍生物或其药学上可接受的盐作为活性成分。 在化学式1中,R是氢或C1-C4的烷氧基。 化学式1的丙烯酰胺衍生物是(E)-4'-羟基-3'-甲氧基苯乙烯基3-(4-羟基苯基)丙酸酯或(R,E)-4'-羟基-3'-甲氧基苯乙烯基-3-(4 羟基苯基)-7-甲氧基丙。 制备丙烯酰胺衍生物的方法包括:用水,C1-C4的醇或混合溶剂提取茄子的步骤; 将提取物悬浮在水中并加入相同量的乙酸乙酯以获得乙酸乙酯级分(第一级分)的步骤; 进行乙酸乙酯级分的硅胶柱色谱以获得第二级分(1-6)的步骤; 进行第二级分的第5级的硅胶柱色谱以获得第三级分(5-1〜5-7)的步骤; 和进行反相18柱色谱的步骤。